PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

ConditionInborn Errors of Immunity

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age0-21

SponsorFederal Research Institute of Pediatric Hematology, Oncology and Immunology

About this trial

The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)

Eligibility criteria

Qualifiers

Patients aged ≥ 0 months and < 21 years

Patients diagnosed with NBS eligible for an allogeneic HSCT

Signed written informed consent signed by a parent or legal guardian

Disqualifiers

None

Trial design

Treatments tested in this trial

Cyclophosphamide
Ruxolitinib

Treatment groups

100 Participants

are divided into 1 treatment group

Sponsors and collaborators

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Lead sponsor

Source ClinicalTrials.gov